Revisiting the advances and challenges in the clinical applications of extracellular vesicles in cancer

G He, J Liu, Y Yu, S Wei, X Peng, L Yang, H Li - Cancer Letters, 2024 - Elsevier
Extracellular vesicles (EVs) have been the subject of an exponentially growing number of
studies covering their biogenesis mechanisms, isolation and analysis techniques …

The Putative Effects of Neoadjuvant Chemotherapy on the Immune System of Advanced Epithelial Ovarian Carcinoma

Y Li, X Gan, F Li, L Hu - Immunological investigations, 2024 - Taylor & Francis
The epithelial ovarian carcinoma (EOC) is one of leading causes of cancer-related mortality
in females. For some patients, complete resection cannot be achieved, thus neoadjuvant …

Metronomic chemotherapy in ovarian cancer

V Garg, L Kumar - Cancer Letters, 2023 - Elsevier
Translational research and the development of targeted therapies have transformed the
therapeutic landscape in epithelial ovarian cancer over the last decade. However, recurrent …

[HTML][HTML] The power and the promise of synthetic lethality for clinical application in cancer treatment

QW Liu, ZW Yang, QH Tang, WE Wang, DS Chu… - Biomedicine & …, 2024 - Elsevier
Synthetic lethality is a phenomenon wherein the simultaneous deficiency of two or more
genes results in cell death, while the deficiency of any individual gene does not lead to cell …

Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway

S Bae, S Bae, HS Kim, YJ Lim, G Kim… - Cancer Management …, 2024 - Taylor & Francis
Background Ovarian cancer is one of women's malignancies with the highest mortality
among gynecological cancers. Paclitaxel is used in first-line ovarian cancer chemotherapy …

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4

A Ghose, L McCann, S Makker… - Therapeutic …, 2024 - journals.sagepub.com
Ovarian cancer (OC) is the most lethal gynaecologic malignancy, attributed to its insidious
growth, non-specific symptoms and late presentation. Unfortunately, current screening …

[HTML][HTML] 12-O-deacetyl-phomoxanthone A inhibits ovarian tumor growth and metastasis by downregulating PDK4

C Yang, S Xing, X Wei, J Lu, G Zhao, X Ma… - Biomedicine & …, 2024 - Elsevier
Aims The xanthone dimer 12-O-deacetyl-phomoxanthone A (12-ODPXA) was extracted from
the secondary metabolites of the endophytic fungus Diaporthe goulteri. The 12-ODPXA …

[HTML][HTML] Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study

T Liu, Y Gao, S Li, S Xu - Journal of Ovarian Research, 2024 - Springer
Background Ovarian clear cell carcinoma (OCCC) is a rare pathological histotype in ovarian
cancer, while the survival rate of advanced OCCC (Stage III-IV) is substantially lower than …

[HTML][HTML] Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting

MFP Maiorano, BA Maiorano, A Biancofiore, G Cormio… - Pharmaceuticals, 2023 - mdpi.com
Ovarian cancer (OC) is the eighth most common cancer among the female population and
the most lethal of all the female reproductive system malignancies. Poly (ADP-ribose) …

Inactivation of VRK1 sensitizes ovarian cancer to PARP inhibition through regulating DNA-PK stability

H Yun, JE You, JU Lee, DH Kang, YS Ryu… - Experimental Cell …, 2024 - Elsevier
Ovarian cancer is the leading cause of gynecologic cancer death. Among the most
innovative anti-cancer approaches, the genetic concept of synthetic lethality is that mutations …